MELBOURNE, Australia, March 26, 2014 /PRNewswire/ --Phosphagenics Limited (ASX: POH) (OTCQX: PPGNY) ("Phosphagenics" or "the Company") announced today that management will host an investor conference call and webcast to discuss the commercial opportunities arising from a range of innovative analgesic products emerging from the Company's patented TPM® drug delivery technology. The Company will describe how TPM® is enabling it to establish a unique competitive position in the transdermal and topical delivery of diverse analgesics, including oxymorphone and oxycodone. The Company will review current success stories, ongoing and future development plans, and the commercial opportunity for unique and innovative products that overcome the limitations of analgesics currently on market.
The Company's CEO, Harry Rosen, CSO, Paul Gavin, General Counsel, Jason Rosen, and VP of Business Development, Alex Stojanovic, will host the call with investors and analysts on the date and time below.
4:00pm EDT (USA) Wednesday, April 2, 2014
7:00am EDT (Australia) Thursday, April 3, 2014
1 800 687 004 (Toll Free)
A replay of the call will be available from 7:00 pm EDT (USA) April 2, 2014 to 11:59 pm EDT (USA) April 9, 2014 (which is 10.00am EDT (Australia) April 3, 2014 to 3.59amApril 10, 2014 (Australia)). To access the replay, use +1-877-870-5176 for US callers, Toll Free 1 800 687 004 for Australian callers, and +1-858-384-5517 for other international callers. The PIN number is 13579254.
"We believe that our products are novel and differentiated offerings for the multi-billion dollar pain therapeutics markets worldwide," began Harry Rosen, CEO of Phosphagenics Limited. "We are especially excited about opportunities to deploy our patented drug delivery system to improve the effectiveness of many analgesics. Phase 1 data on our TPM®/Oxymorphone and TPM®/Oxycodone patches have delivered outstanding results, including the delivery of therapeutic amounts of drug at a constant rate for the duration of patch application, rapid elimination after patch removal and minimal skin irritation at the application site. We are the first company in the world that has been able to deliver such levels of these molecules transdermally, a result that has promoted early commercial discussions with potential licensees. This is an exciting time for Phosphagenics, as we are now preparing for an IND in the US and moving toward initiation of pivotal Phase 2/3 trials."
Phosphagenics Limited is a biotechnology company that is commercializing various products within the pharmaceutical, cosmetics, and animal health sectors, using its proprietary drug delivery system called TPM® (Targeted Penetration Matrix). TPM® is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain.
Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR Level 1 program in the US is with The Bank of New York Mellon (PPGNY).
This presentation, and any representations made before, during or after the presentation, may include forward-looking statements that are inherently subject to risks and uncertainties. These statements relate to, but are not limited to: (1) the safety or efficacy of, or potential applications for, Phosphagenics' TPM platform technology; (2) the strength of Phosphagenics' intellectual property; (3) the timelines for Phosphagenics' clinical trials and regulatory processes for its different products; (4) the scalability and efficiency of manufacturing processes; (5) revenue projections, market share expectations, share price expectations and capital requirements.
Actual results may differ from the expectations expressed in these forward-looking statements, and the differences may be material (whether positive or negative). The risks that may cause Phosphagenics' actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, include but are not limited to: (1) risks inherent in the development, approval and commercialization of potential products; (2) uncertainty of clinical trial results or regulatory approvals or clearances; (3) changes to market trends or government laws or regulations; (4) the potential need for future capital; (5) dependence upon collaborators; and (6) protection of intellectual property rights, among others. Accordingly, you should not place undue reliance on these forward-looking statements.
Investor Relations Australia
David Segal, Investor Relations Manager
Investor Relations USA
MZ North America
John Mattio, SVP
SOURCE Phosphagenics Limited